文献速递糖尿病

钠-葡萄糖共转运蛋白2抑制剂与膝下截肢风险:一项多中心观察性研究

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study.
PubMed 文献 · Diabetes Care · 2020-08-05

该多中心观察性研究利用加拿大七个省份和英国的医疗行政数据库,将207,817例新使用SGLT2抑制剂的患者与207,817例新使用DPP-4抑制剂的患者按时间条件倾向评分匹配。平均暴露随访11个月期间,SGLT2抑制剂组膝下截肢率为1.3/1000人年,DPP-4抑制剂组为1.5/1000人年,校正HR为0.88(95%CI 0.71-1.09),未发现SGLT2抑制剂使用与膝下截肢相关。

要点

  • SGLT2抑制剂组与DPP-4抑制剂组各207,817例,平均暴露随访11个月。
  • 膝下截肢率SGLT2抑制剂组1.3/1000人年 vs DPP-4抑制剂组1.5/1000人年。
  • 校正HR为0.88(95%CI 0.71-1.09),未见与膝下截肢的关联。

核心结论

  • 在2型糖尿病患者中,与DPP-4抑制剂相比,SGLT2抑制剂使用与膝下截肢无关联。
  • 作者指出这些发现提供了一定 reassurance,但需更长期随访研究评估潜在长期效应。

研究设计与样本

  • 多中心观察性研究,使用加拿大七个省份和英国的医疗行政数据库。
  • 采用现患新用户设计与时间条件倾向评分,将新使用SGLT2抑制剂者与新使用DPP-4抑制剂者匹配。
  • 队列纳入207,817例新使用SGLT2抑制剂者,匹配207,817例新使用DPP-4抑制剂者。
  • 采用Cox比例风险模型估计各站点校正HR及95%CI,并用随机效应Meta分析合并各站点结果。

主要发现

  • 平均暴露随访时间为11个月。
  • 膝下截肢率:SGLT2抑制剂组1.3/1000人年,DPP-4抑制剂组1.5/1000人年。
  • SGLT2抑制剂使用相较DPP-4抑制剂使用的膝下截肢校正HR为0.88(95%CI 0.71-1.09)。
  • 按具体SGLT2抑制剂分子分层分析得到相似结果。

局限性

  • 作者指出需要更长期随访的研究来评估潜在的长期效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Reports of amputations associated with sodium-glucose cotransporter 2 (SGLT2) inhibitors have been inconsistent. We aimed to compare the risk of below-knee amputation with SGLT2 inhibitors versus dipeptidyl peptidase 4 (DPP-4) inhibitors among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This multicenter observational study used administrative health care databases from seven Canadian provinces and the U.K. Incident SGLT2 inhibitor users were matched to DPP-4 inhibitor users using a prevalent new-user design and time-conditional propensity scores. Cox proportional hazards models were used to estimate site-specific adjusted hazard ratios (HR) and corresponding 95% CIs of incident below-knee amputation for SGLT2 inhibitor versus DPP-4 inhibitor users. Random effects meta-analyses were used to pool the site-specific results. RESULTS: The study cohort included 207,817 incident SGLT2 inhibitor users matched to 207,817 DPP-4 inhibitor users. During a mean exposed follow-up time of 11 months, the amputation rate was 1.3 per 1,000 person-years among SGLT2 inhibitor users and 1.5 per 1,000 person-years among DPP-4 inhibitor users. The adjusted HR of below-knee amputations associated with SGLT2 inhibitor use compared with DPP-4 inhibitor use was 0.88 (95% CI 0.71-1.09). Similar results were obtained in stratified analyses by specific SGLT2 inhibitor molecule. CONCLUSIONS: In this large multicenter observational study, there was no association between SGLT2 inhibitor use and incident below-knee amputations among patients with type 2 diabetes compared with DPP-4 inhibitor use. While these findings provide some reassurance, studies with a longer duration of follow-up are needed to assess potential long-term effects.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Yu OHY, Dell'Aniello S, Shah BR, et al. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. Diabetes Care. 2020. PMID: 32759360. doi:10.2337/dc20-0267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。